Prostate Cancer Crpc clinical trials

Explore recruiting prostate cancer crpc clinical trials.

Recruiting prostate cancer crpc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Prostate Cancer Crpc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Spain, Latvia, Lithuania

Therapeutic confirmatory (Phase III) EU CTIS Study details

PEACE 6 Vulnerable : A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents.

France, Spain, Ireland, Belgium, Italy, Romania +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

EORTC 1333-GU: A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone (PEACE III)

Poland, Italy, Spain, Belgium, Ireland, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer

Hungary, Spain, Italy, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

Belgium, Finland, France, Germany, Netherlands, Bulgaria +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with androgen receptor pathway inhibitors in patients with PSMA PET scan positive castration-resistant prostate cancer (PSMACare)

Spain, Germany, Italy, Netherlands, Czechia, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Prostate Cancer Crpc trials by city

Prostate Cancer Crpc in Toronto Prostate Cancer Crpc in Vancouver Prostate Cancer Crpc in Montreal Prostate Cancer Crpc in Calgary Prostate Cancer Crpc in Edmonton Prostate Cancer Crpc in Ottawa Prostate Cancer Crpc in Winnipeg Prostate Cancer Crpc in Quebec City Prostate Cancer Crpc in Hamilton Prostate Cancer Crpc in Kitchener Prostate Cancer Crpc in London Prostate Cancer Crpc in Halifax Prostate Cancer Crpc in New York Prostate Cancer Crpc in Los Angeles Prostate Cancer Crpc in Chicago Prostate Cancer Crpc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease